Trial Outcomes & Findings for Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) (NCT NCT00626444)
NCT ID: NCT00626444
Last Updated: 2025-05-16
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
2 participants
Primary outcome timeframe
10 weeks
Results posted on
2025-05-16
Participant Flow
Participant milestones
| Measure |
Vitamin C
Intravenous vitamin C
Intravenous vitamin C: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
|
|---|---|
|
Overall Study
STARTED
|
2
|
|
Overall Study
COMPLETED
|
2
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
Baseline characteristics by cohort
| Measure |
Vitamin C
n=2 Participants
Intravenous vitamin C
Intravenous vitamin C: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
|
|---|---|
|
Age, Continuous
|
55.3 years
STANDARD_DEVIATION 2.9 • n=5 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
2 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 10 weeksOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 10 weeksOutcome measures
Outcome data not reported
Adverse Events
Vitamin C
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Vitamin C
n=2 participants at risk
Intravenous vitamin C
Intravenous vitamin C: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
|
|---|---|
|
General disorders
Abdominal pain
|
50.0%
1/2 • Number of events 1
|
|
General disorders
Back pain
|
50.0%
1/2 • Number of events 1
|
|
General disorders
Induration at IV site
|
50.0%
1/2 • Number of events 1
|
|
General disorders
Lightheadedness
|
50.0%
1/2 • Number of events 1
|
|
General disorders
Nausea
|
50.0%
1/2 • Number of events 1
|
|
General disorders
Pain at IV site
|
50.0%
1/2 • Number of events 3
|
|
General disorders
Viral illness
|
50.0%
1/2 • Number of events 1
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place